Research Article

Subthreshold $\alpha_2$-Adrenergic Activation Counteracts Glucagon-Like Peptide-1 Potentiation of Glucose-Stimulated Insulin Secretion

Minglin Pan,1 Guang Yang,1 Xiuli Cui,1 and Shao-Nian Yang1,2

1 Endocrinology and Metabolic Diseases Laboratory, Tianjin Research Center of Basic Medical Sciences and Metabolic Diseases Hospital, Tianjin Medical University, Tianjin 300070, China
2 The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, 171 76 Stockholm, Sweden

Correspondence should be addressed to Shao-Nian Yang, yangshaonian@tijmu.edu.cn

Received 10 October 2010; Accepted 10 December 2010

Academic Editor: Carlo M. Rotella

Copyright © 2011 Minglin Pan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The pancreatic $\beta$ cell harbors $\alpha_2$-adrenergic and glucagon-like peptide-1 (GLP-1) receptors on its plasma membrane to sense the corresponding ligands adrenaline/noradrenaline and GLP-1 to govern glucose-stimulated insulin secretion. However, it is not known whether these two signaling systems interact to gain the adequate and timely control of insulin release in response to glucose. The present work shows that the $\alpha_2$-adrenergic agonist clonidine concentration-dependently depresses glucose-stimulated insulin secretion from INS-1 cells. On the contrary, GLP-1 concentration-dependently potentiates insulin secretory response to glucose. Importantly, the present work reveals that subthreshold $\alpha_2$-adrenergic activation with clonidine counteracts GLP-1 potentiation of glucose-induced insulin secretion. This counteraction process relies on pertussis toxin- (PTX-) sensitive Gi proteins since it no longer occurs following PTX-mediated inactivation of Gi proteins. The counteraction of GLP-1 potentiation of glucose-stimulated insulin secretion by subthreshold $\alpha_2$-adrenergic activation is likely to serve as a molecular mechanism for the delicate regulation of insulin release.

1. Introduction

Glucose-stimulated insulin secretion plays an irreplaceable role in the control of glucose homeostasis since insulin is the only hormone capable of lowering blood glucose in the body [1–3]. This pancreatic endocrine hormone is packed in $\beta$ cell secretory granules. These granules undergo exocytosis to release their insulin cargo into the bloodstream in response to elevated blood glucose levels [1–3]. Upon elevation of the plasma glucose level, the $\beta$ cell efficiently takes up glucose through glucose transporters. Thereafter, subsequent glucose metabolism drastically raises the intracellular ATP level. The resultant rise in the ATP/ADP ratio closes ATP-sensitive $K^+$ (KATP) channels, causing depolarization of the plasma membrane. The membrane depolarization in turn opens voltage-gated $Ca^{2+}$ (CaV) channels, mediating $Ca^{2+}$ influx. The consequent increase in cytosolic-free $Ca^{2+}$ concentration ([Ca$^{2+}$]) triggers direct interactions between exocytotic proteins situated in the insulin-containing granule membrane and those localized in the plasma membrane. Eventually, the interaction between exocytotic proteins initiates the fusion of insulin-containing granules with the plasma membrane, that is, insulin exocytosis [1–3].

On top of the aforementioned consensus paradigm, glucose-stimulated insulin secretion is, in fact, regulated by complex neural mechanisms [4, 5]. It is well known that the autonomic nervous system innervates pancreatic islet cells where parasympathetic endings release a bunch of substances, for example, acetylcholine and vasoactive intestinal polypeptide, to potentiate glucose-stimulated insulin secretion [5, 6]. On the contrary, sympathetic terminals exocytose adrenergic and peptidergic transmitters to inhibit the insulin secretory process [4, 5]. Treatment with the main sympathetic transmitter noradrenaline fully shuts down insulin secretion from either islets or $\beta$ cell aggregates perfused with high glucose [7, 8]. Mechanistically noradrenaline acts on $\alpha_2$ receptors coupled to pertussis toxin- (PTX-) sensitive Gi proteins in $\beta$ cells, reducing glucose-stimulated
insulin secretion through inhibition of intracellular cAMP formation, CaV channels, glucose metabolism, and the exocytic machinery as well as elevation of KATP channel activity [4, 5].

Glucose-stimulated insulin secretion is subjected not only to the complex neural regulation, but also to various different types of hormonal regulation [9–16]. The islet β cell is able to sense its own released molecules, such as zinc and ATP, and hormones released from its neighboring cells to autocrinally and paracrinally regulate insulin secretion in response to glucose stimulation [13–18]. A number of systemic hormones impinge on islet β cells to coordinate insulin secretory response to glucose [9–12, 19]. A group of gastrointestinal hormones has long attracted a great deal of attention and categorized as incretins due to their stimulatory action on glucose-stimulated insulin secretion [9–12]. One of the most important incretin hormones is glucagon-like peptide-1 (GLP-1), which is secreted from intestinal L-cells into the bloodstream after a meal [9–12]. Upon encounter with β cells, this incretin binds to Gs protein-coupled receptors on these cells, resulting in activation of adenyl cyclases, CaV channels, glucose metabolism, and the exocytotic machinery as well as inhibition of KATP channels [9–12, 20–22]. As consequence of these events, potentiation of glucose-stimulated insulin secretion occurs [9–12, 20–22].

Although either noradrenergic or GLP-1 signaling system in the regulation of glucose-stimulated insulin secretion has been clarified, it is not known whether these two signaling systems interact to gain adequate and timely insulin release in response to glucose stimulation [4, 5, 9–12, 20–22]. In the present work, we describe that subthreshold α2-adrenergic activation counteracts glucagon-like peptide-1 potentiation of glucose-stimulated insulin secretion in a PTX-sensitive Gi protein-dependent manner.

2. Materials and Methods

2.1. Cell Culture. INS-1 cells were cultivated in RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with the following additives: 10% fetal bovine serum, 2 mM L-glutamine, and 100 U/100 μg/ml penicillin/streptomycin, 10 mM N-[2-hydroxyethyl]piperazine-N′-2-ethanesulfonic acid (HEPES), 1 mM sodium pyruvate, and 50 μM β-mercaptoethanol (Invitrogen). Briefly, the cells at about 70% confluency were trypsinized. The resultant cell suspension was seeded into 24-well cell culture plates. The cells were maintained at 37°C in a humidified 5% CO2 incubator. They were grown to approximately 70% confluence and then subjected to analysis of insulin secretion.

2.2. Static Insulin Secretion. Approximately 70% confluent INS-1 cells in 24-well plates were used for insulin secretion experiments. The cells were kept at 37°C in a humidified 5% CO2 incubator during the course of an experiment except when their bath solutions need to be changed. The experiments were carried out in Krebs-Ringer bicarbonate HEPES buffer (KRHB) consisting of (in mM) 140NaCl, 3.6KCl, 1.5CaCl2, 0.5MgSO4, 0.5NaH2PO4, 2NaHCO3, 10HEPES, 0.1% bovine serum albumin (BSA), pH 7.4. First, the cells were rinsed with glucose-free KRHB and then maintained in the same buffer for 2 h. Thereafter, they were rinsed and preincubated with glucose-free KRHB for 30 min. To characterize the concentration-response relationships of the α2-adrenergic agonist clonidine and the incretin GLP-1 as well as interactions between noradrenergic and GLP-1 signaling systems, the cells were rinsed and incubated with 3 or 11 mM glucose KRHB containing different concentrations of clonidine and/or GLP-1 for 30 min. Clonidine and/or GLP-1 were applied simultaneously with glucose. To determine a possible dependence of α2-adrenoceptor regulation of GLP-1 receptors on PTX-sensitive Gi proteins, the cells were pretreated with 100 ng/ml PTX in RPMI 1640 medium for 18 h. Subsequently, the toxin medium was removed. The cells were rinsed and incubated with glucose-free KRHB as described above and subjected to incubations with 3 or 11 mM glucose KRHB containing different concentrations of clonidine and/or GLP-1 for 30 min. Finally, the treatments with the different reagents were stopped by putting the culture plates on ice. Supernatants were carefully aspirated from each well to prepare samples for insulin quantification. The samples were centrifuged at 1000 × g for 3 min to remove detached cells and stored at −20°C until insulin immunoassay was performed.

2.3. Radioimmunoassay. A standard insulin immunoassay was used to evaluate static insulin secretion from INS-1 cells subjected to different treatments [23, 24]. Briefly, duplicate samples were measured. The calibration curve was constructed from insulin standard at 5, 10, 20, 40, 80, and 160 mIU/L. Radioactivity was counted by a γ-counter.

2.4. Statistical Analysis. All data are presented as mean ± SEM. Statistical significance was evaluated by one-way ANOVA, followed by least significant difference (LSD) test. The significance level was determined at both the 0.05 and 0.01 levels.

3. Results

3.1. Clonidine Concentration-Dependently Inhibits Glucose-Stimulated Insulin Secretion. To determine the concentration response relationship of clonidine inhibition of glucose-stimulated insulin secretion, we examined the effect of 30 min incubation with clonidine at concentrations ranging from 0.003 to 10 μM on insulin release from INS-1 cells challenged with 11 mM glucose. As shown in Figure 1, incubation with 11 mM glucose for 30 min resulted in a significant insulin secretion as compared with that with 3 mM glucose (n = 6, P < .01). This confirms that the cells used in this set of experiments reliably responded to such stimulation to secrete an appreciable amount of insulin. We therefore adopted this sufficient and reliable stimulation to test for the effect of clonidine on glucose-stimulated insulin secretion. Figure 1 shows that in the concentration range of 0.003–10 μM, clonidine concentration-dependently inhibited insulin release from INS-1 cells exposed to 11 mM
The α2-adrenergic agonist clonidine concentration-dependently depresses glucose-stimulated insulin secretion from INS-1 cells. Static insulin secretion was performed with cells subjected to stepwise elevation of glucose concentration from 3 to 11 mM for 30 min in the absence or presence of clonidine and determined by a standard insulin radioimmunoassay. Cells exposed to 11 mM glucose (closed circle at the far left) released significantly more insulin than those to 3 mM glucose (open circle) \( (n = 6, P < .01) \). In the concentration range of 0.003–10 μM, clonidine produced a concentration-dependent inhibition of insulin release induced by 11 mM glucose. The inhibition became statistically significant at 0.01 μM clonidine \( (n = 6, P < .05) \) and was statistically significant at higher clonidine concentrations \( (n = 6, P < .01) \). The subthreshold and ED50 concentration of clonidine were calculated to be 0.003 and 4 μM, respectively. In this and all other figures, data are presented as means ± SEM. Statistical significance was evaluated by one-way ANOVA, followed by least significant difference (LSD) test. *\( P < .05 \) and **\( P < .01 \) versus 11 mM glucose-treated group.

3.2. Glucagon-Like Peptide-1 Concentration-Dependently Stimulates Glucose-Stimulated Insulin Secretion. To reveal the concentration-response relationship of GLP-1 potentiation of glucose-stimulated insulin secretion, we evaluated the insulin secretory response of INS-1 cells stimulated with 11 mM glucose for 30 min in the presence of GLP-1 in the concentration range 0.0001 to 1000 nM. Figure 2 shows that 11 mM glucose treatment for 30 min produced a significant increase in insulin secretion in comparison with 3 mM glucose treatment \( (n = 6, P < .01) \). This validates that the glucose responsiveness of the cells employed in this set of experiments. As illustrated in Figure 2, GLP-1 in the concentration range 0.0001 to 1000 nM significantly potentiated insulin release induced by 11 mM glucose in a concentration-dependent manner. The statistically significant potentiation occurred when GLP-1 concentration was raised to 0.1 nM and higher \( (n = 6, P < .01 \) versus 3 mM glucose-treated group). The subthreshold and ED50 concentration of GLP-1 were estimated to be 0.01 and 0.1 nM, respectively. **\( P < .01 \) versus 11 mM glucose-treated group.

3.3. Subthreshold Clonidine Suppresses the Stimulatory Effect of Glucagon-Like Peptide-1 on Glucose-Stimulated Insulin Secretion. The pancreatic β cell is equipped with both the α2-adrenergic receptor and the GLP-1 receptor which are impinged by the sympathetic transmitter adrenaline/noradrenaline and the incretin hormone GLP-1, respectively \[4, 5, 9–12, 20–22\]. Both of these systems critically regulate glucose-stimulated insulin secretion \[4, 5, 9–12, 20–22\]. This inevitably raises the question whether they are insulated from each other or one cross-talks with...
the other in pancreatic β cells. To tackle this issue, we examined how subthreshold α2-adrenergic activation affects GLP-1 potentiation of glucose-stimulated insulin secretion.

Validation of the capacity of the cells applied in this set of experiments to release insulin in response to glucose was likewise performed. As illustrated in Figure 3, treatment with 11 mM glucose for 30 min gave rise to a significant insulin release as compared with that with 3 mM glucose (n = 10, P < .01). As expected, cells exposed to clonidine at the subthreshold concentration 3 nM did not alter their insulin secretory response to 11 mM glucose (n = 10, P > .05 versus group subjected to only 11 mM glucose stimulation) (Figure 3). In contrast, cells treated with GLP-1 at the ED50 concentration 0.1 nM following 11 mM glucose stimulation released significantly more insulin than cells subjected to only 11 mM glucose stimulation (n = 10, P < .01). Importantly, cells incubated with the ED50 concentration of GLP-1 plus the subthreshold concentration of clonidine secreted significantly less insulin than cells treated with the ED50 concentration of GLP-1 alone following 11 mM glucose stimulation (n = 10, P < .01) (Figure 3). The insulin secretory response to 11 mM glucose was very similar among group treated with the ED50 concentration of GLP-1 plus the subthreshold concentration of clonidine, group treated with the subthreshold concentration of clonidine alone, and untreated group (n = 10, P > .05) (Figure 3). The data demonstrate that the subthreshold concentration of clonidine completely counteracted the potentiation of glucose-stimulated insulin secretion by the ED50 concentration of GLP-1.

3.4. Counteraction of Glucagon-Like Peptide-1 Potentiation of Glucose-Stimulated Insulin Secretion by Clonidine Relies on Pertussis Toxin-Sensitive Gi Proteins. Multiple intracellular signaling events, such as decreases in cAMP production, CaV channel activity, glucose metabolism, and exocytotic capacity as well as an increase in KATP conductance occur upon activation of α2-adrenergic receptors on the β cell to depress glucose-stimulated insulin secretion [4, 5]. All these events are dependent on the PTX-sensitive Gi protein that is an immediate mediator for α2-adrenergic activation [4, 5].

This made us wonder if counteraction of GLP-1 potentiation of glucose-stimulated insulin secretion by clonidine relies on PTX-sensitive Gi proteins. To circumvent this issue, we evaluated if PTX-mediated inactivation of Gi proteins could prevent counteraction of GLP-1 potentiation of glucose-stimulated insulin secretion by subthreshold α2-adrenergic activation.

The cells used in this set of experiments were proved to be quite sensitive to glucose with regard to their insulin secretory responsiveness. Figure 4 shows that both control and PTX-pretreated cells released a significant amount of insulin when glucose concentration was raised from 3 to 11 mM (n = 11, P < .01). Cells pretreated with 100 ng/ml PTX in for 18 h secreted significantly more insulin than cells without PTX pretreatment following 11 mM glucose stimulation (n = 11, P < .01) (Figure 4). Clonidine at both the subthreshold concentration 3 nM and the ED50 concentration 4 μM had no effect on insulin secretory response to 11 mM glucose in PTX-pretreated cells (n = 11, P > .05 versus PTX-pretreated group subjected to only 11 mM glucose stimulation) (Figure 4). However, GLP-1 at the ED50 concentration 0.1 nM significantly enhanced insulin secretion from PTX-pretreated cells following 11 mM glucose stimulation (n = 11, P < .01 versus PTX-pretreated group subjected to only 11 mM glucose stimulation) (Figure 4). Most importantly, the subthreshold concentration of clonidine was unable to counteract potentiation of glucose-stimulated insulin secretion by the ED50 concentration of GLP-1 in PTX-pretreated cells (n = 11, P > .05 versus PTX-pretreated group treated with 11 mM glucose plus 0.1 nM GLP-1) (Figure 4). The data reveal that counteraction of GLP-1 potentiation of glucose-stimulated insulin secretion by clonidine relies on PTX-sensitive Gi proteins.
induced insulin release \([4, 5, 9–12]\). The present work confirms that the \(\alpha_2\)-adrenergic agonist clonidine and the incretin GLP-1 concentration-dependently inhibits glucose-induced insulin release at concentration ranges similar to those employed in previous studies \([8, 25, 26]\). Furthermore, it also estimates the subthreshold and \(ED_{50}\) concentration of these two agonists. These parameters are critical for examination of the counteraction of GLP-1 potentiation of glucose-stimulated insulin secretion by subthreshold \(\alpha_2\)-adrenergic activation.

Most importantly, the present study shows for the first time that insulin-secreting INS-1 cells exposed to the \(ED_{50}\) concentration of GLP-1 together with the subthreshold concentration of clonidine release significantly less insulin than cells treated with the \(ED_{50}\) concentration of GLP-1 alone following glucose stimulation. Furthermore, it also uncovers that the antagonistic interaction of the \(\alpha_2\)-adrenergic signaling system with the GLP-1 signaling system critically depends on PTX-sensitive Gi proteins. These findings provide evidence that \(\alpha_2\)-adrenergic or GLP-1 signaling systems do not operate independently, but instead the former effectively antagonizes the latter to enable the pancreatic \(\beta\) cell to appropriately execute its unique function glucose-stimulated insulin secretion. In fact, interactions between G protein-coupled receptor signaling pathways have been intensively investigated in other cell types and neurons in particular \([27–33]\). Such interactions rely on multilevel mechanisms \([27–33]\). They occur at the receptor level due to receptor heterodimerization, which is either G protein-dependent or -independent \([27–30]\). The heterodimerization is able to alter the ligand binding affinity and/or signal transduction efficacy of dimerized receptors \([27–30, 32, 33]\). Interactions between G protein-coupled receptor signaling pathways can also bypass the receptor level and come about downstream of receptors as a result of crosstalk between receptor signaling cascades \([31]\). In general, these well-characterized mechanisms are applicable to the counteraction of GLP-1 potentiation of glucose-stimulated insulin secretion by subthreshold \(\alpha_2\)-adrenergic activation in the pancreatic \(\beta\) cell. The in-depth mechanisms whereby the \(\alpha_2\)-adrenergic signaling system antagonizes the GLP-1 signaling system in the pancreatic \(\beta\) cell remain to be characterized.

There is no doubt that the healthy body requires the efficient amount of insulin to remove extra glucose from the blood stream into body cells most of the time. However, the healthy body needs less insulin to boost blood glucose levels in some circumstances, such as stress, exercise, low blood glucose, and other environmental challenges. The counteraction of GLP-1 potentiation of glucose-stimulated insulin secretion by subthreshold \(\alpha_2\)-adrenergic activation definitely fits in with these circumstances where sympathetic activity is elevated \([34]\). It adds a new level of complexity to the classical paradigm for the regulation of glucose-evoked insulin release. Under certain pathological conditions, for example, diabetes, hypertension, obesity, and aging, sympathetic activity and/or expression of \(\alpha_2\)-adrenergic receptors in the \(\beta\) cell significantly increase \([35–39]\). Increases in sympathetic activity and/or expression of \(\alpha_2\)-adrenergic receptors in the \(\beta\) cell likely exaggerate the antagonistic response.
interaction of the $\alpha_2$-adrenergic signaling system with the GLP-1 signaling system in the pancreatic $\beta$ cell to provoke and aggravate diabetes [35–39].

5. Conclusions

$\alpha_2$-Adrenergic receptors and GLP-1 receptors on insulin-secreting INS-1 cells transduce signals from their corresponding ligands clonidine and GLP-1 to govern glucose-induced insulin release. Importantly, the former also interacts with the latter to brake potentiation of glucose-induced insulin release by the latter. In fact, subthreshold $\alpha_2$-adrenergic activation is enough to counteract GLP-1 potentiation of glucose-induced insulin secretion in a PTX-sensitive Gi protein-dependent fashion. Such a counteraction is able to serve as a molecular mechanism for the delicate control of insulin release in the healthy body. Most likely, this counteractive process is exaggerated to provoke and aggravate diabetes since obesity, aging, and diabetes are highly associated with elevated sympathetic activity [35–39].

Acknowledgments

This work was supported by Grants from National Natural Science Foundation of China (30971175) and Tianjin Municipal Science and Technology Commission (09JCZDJC1990), a start-up research grant from Tianjin Medical University. Minglin Pan and Guang Yang contributed equally to this work.

References

[1] S. N. Yang and P. O. Berggren, “$\beta$-cell $\lambda_1$ channel regulation in physiology and pathophysiology,” American Journal of Physiology, vol. 288, no. 1, pp. E16–E28, 2005.
[2] S. N. Yang and P. O. Berggren, “Cav-2.3 channel and PKCζ: new players in insulin secretion,” Journal of Clinical Investigation, vol. 115, no. 1, pp. 16–20, 2005.
[3] S. N. Yang and P. O. Berggren, “The role of voltage-gated calcium channels in pancreatic $\beta$-cell physiology and pathophysiology,” Endocrine Reviews, vol. 27, no. 6, pp. 621–676, 2006.
[4] G. W. Sharp, “Mechanisms of inhibition of insulin release,” American Journal of Physiology, vol. 271, no. 6, pp. C1781–C1799, 1996.
[5] B. Ahrén, “Autonomic regulation of islet hormone secretion—implications for health and disease,” Diabetologia, vol. 43, no. 4, pp. 393–410, 2000.
[6] P. Gilon and J. C. Henquin, “Mechanisms and physiological significance of the cholinergic control of pancreatic $\beta$-cell function,” Endocrine Reviews, vol. 22, no. 5, pp. 565–604, 2001.
[7] T. Nilsson, P. Arkhammar, P. Rorsman, and P. O. Berggren, “Inhibition of glucose-stimulated insulin release by $\alpha_2$-adrenoceptor antagonists on isolated pancreatic islets,” British Journal of Pharmacology, vol. 79, no. 2, pp. 415–420, 1983.
[9] J. J. Holst, “The physiology of glucagon-like peptide 1,” Physiological Reviews, vol. 87, no. 4, pp. 1409–1439, 2007.
[10] T. J. Kieffer and J. F. Habener, “The glucagon-like peptides,” Endocrine Reviews, vol. 20, no. 6, pp. 876–913, 1999.
[11] W. Kim and J. M. Egan, “The role of incretins in glucose homeostasis and diabetes treatment,” Pharmacological Reviews, vol. 60, no. 4, pp. 470–512, 2008.
[12] J. Gromada, B. Brock, O. Schmitz, and P. Rorsman, “Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential,” Basic & Clinical Pharmacology & Toxicology, vol. 95, no. 6, pp. 252–262, 2004.
[13] A. C. Hauge-Evans, A. J. King, D. Carmignac et al., “Somatostatin secreted by islet $\delta$-cells fulfills multiple roles as a paracrine regulator of islet function,” Diabetes, vol. 58, no. 2, pp. 403–411, 2009.
[14] K. Moens, V. Berger, J. M. Ahn et al., “Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic $\beta$-cells,” Diabetes, vol. 51, no. 3, pp. 669–675, 2002.
[15] N. Ueno, A. Imui, A. Asakawa, H. Yuzuriha, M. Kasuga, and M. Fujimiya, “Impaired glucose tolerance in pancreatic polypeptide-overexpressing mice,” Diabetologia, vol. 45, no. 7, pp. 1048–1049, 2002.
[16] M. K. Reimer, G. Pacini, and B. Ahrén, “Dose-dependent inhibition by ghrelin of insulin secretion in the mouse,” Endocrinology, vol. 144, no. 3, pp. 916–921, 2003.
[17] M. C. Jacques-Silva, M. Correa-Medina, O. Cabrera et al., “ATP-gated P2X3 receptors constitute a positive autocrine signal for insulin release in the human pancreatic $\beta$ cell,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 14, pp. 6465–6470, 2010.
[18] R. Ferrer, B. Soria, C. M. Dawson, I. Atwater, and E. Rojas, “Effects of Zn$^{2+}$ on glucose-induced electrical activity and insulin release from mouse pancreatic islets,” American Journal of Physiology, vol. 246, no. 5, pp. C520–C527, 1984.
[19] C. Lambillotte, P. Gilon, and J. C. Henquin, “Direct glucocorticoid inhibition of insulin secretion: an in vitro study of dexamethasone effects in mouse islets,” Journal of Clinical Investigation, vol. 99, no. 3, pp. 414–423, 1997.
[20] J. Gromada, K. Bokvist, W. G. Ding, J. J. Holst, J. H. Nielsen, and P. Rorsman, “Glucagon-like peptide 1(7–36)amide stimulates exocytosis in human pancreatic $\beta$-cells by both proximal and distal regulatory steps in stimulus-secretion coupling,” Diabetologia, vol. 47, no. 1, pp. 57–65, 1998.
[21] J. Gromada, J. J. Holst, and P. Rorsman, “Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1,” Pflugers Archiv European Journal of Physiology, vol. 435, no. 5, pp. 583–594, 1998.
[22] J. Gromada, W. G. Ding, S. Barg, E. Renström, and P. Rorsman, “Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors,” Pflugers Archiv European Journal of Physiology, vol. 434, no. 5, pp. 515–524, 1997.
[23] S. N. Yang, O. Larsson, R. Brännström et al., “Syntxin 1 interacts with the LD subtype of voltage-gated Ca$^{2+}$ channels in pancreatic $\beta$ cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 18, pp. 10164–10169, 1999.
[24] J. Yu, P. O. Berggren, and C. J. Barker, “An autocrine insulin feedback loop maintains pancreatic $\beta$-cell 3-phosphorylated inositol lipids,” Molecular Endocrinology, vol. 21, no. 11, pp. 2775–2784, 2007.
[25] S. Ullrich and C. B. Wollheim, “Islet cyclic AMP levels are not lowered during α2-adrenergic inhibition of insulin release,” *Journal of Biological Chemistry*, vol. 259, no. 7, pp. 4111–4115, 1984.

[26] M. Shigeto, M. Katsura, M. Matsuda, S. Ohkuma, and K. Kaku, “Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway,” *Journal of Pharmacological Sciences*, vol. 108, no. 3, pp. 274–279, 2008.

[27] K. Fuxe, D. Marcellino, D. Guidolin, A. S. Woods, and L. F. Agnati, “Heterodimers and receptor mosaics of different types of G-protein-coupled receptors,” *Physiology*, vol. 23, no. 6, pp. 322–332, 2008.

[28] K. Fuxe, D. Marcellino, G. Leo, and L. F. Agnati, “Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis,” *Current Opinion in Pharmacology*, vol. 10, no. 1, pp. 14–22, 2010.

[29] L. F. Agnati, K. Fuxe, I. Zini, P. Lenzi, and T. Hökfelt, “Aspects on receptor regulation and isoreceptor identification,” *Medical Biology*, vol. 58, no. 4, pp. 182–187, 1980.

[30] L. F. Agnati, K. Fuxe, M. Zoli, C. Rondanini, and S. O. Ogren, “New vistas on synaptic plasticity: the receptor mosaic hypothesis of the engram,” *Medical Biology*, vol. 60, no. 4, pp. 183–190, 1982.

[31] T. D. Werry, G. F. Wilkinson, and G. B. Willars, “Mechanisms of cross-talk between G-protein-coupled receptors resulting in enhanced release of intracellular Ca2+,” *Biochemical Journal*, vol. 374, no. 2, pp. 281–296, 2003.

[32] S. N. Yang, D. R. Fior, A. C. Hansson et al., “Increased potency of neuropeptide Y to antagonize α2-adrenoceptor function in the nucleus tractus solitarii of the spontaneously hypertensive rat,” *Neuroscience*, vol. 78, no. 3, pp. 803–813, 1997.

[33] S. N. Yang, S. Dasgupta, P. M. Lledo, J. D. Vincent, and K. Fuxe, “Reduction of dopamine D2 receptor transduction by activation of adenosine A3a receptors in stably A2a/D2 (long-form) receptor co-transfected mouse fibroblast cell lines: studies on intracellular calcium levels,” *Neuroscience*, vol. 68, no. 3, pp. 729–736, 1995.

[34] S. C. Malpas, “Sympathetic nervous system overactivity and its role in the development of cardiovascular disease,” *Physiological Reviews*, vol. 90, no. 2, pp. 513–557, 2010.

[35] S. H. Carlson, J. Shelton, C. R. White, and J. M. Wyss, “Elevated sympathetic activity contributes to hypertension and salt sensitivity in diabetic obese Zucker rats,” *Hypertension*, vol. 35, no. 1, pp. 403–408, 2000.

[36] J. R. Greenfield and L. V. Campbell, “Role of the autonomic nervous system and neuropeptides in the development of obesity in humans: targets for therapy?,” *Current Pharmaceutical Design*, vol. 14, no. 18, pp. 1815–1820, 2008.

[37] A. H. Rosengren, R. Jokubka, D. Toijar et al., “Overexpression of α3A-adrenergic receptors contributes to type 2 diabetes,” *Science*, vol. 327, no. 5962, pp. 217–220, 2010.

[38] F. M. Gribble, “α3A-adrenergic receptors and type 2 diabetes,” *The New England Journal of Medicine*, vol. 362, no. 4, pp. 361–362, 2010.

[39] G. W. Lambert, N. E. Straznicky, E. A. Lambert, J. B. Dixon, and M. P. Schlaich, “Sympathetic nervous activation in obesity and the metabolic syndrome—causes, consequences and therapeutic implications,” *Pharmacology and Therapeutics*, vol. 126, no. 2, pp. 159–172, 2010.